AB Science will host live webcast on phase 3 interim analysis in ALS on 8 April 2016, from 5.30pm to 6.30pm CET

PARIS, April 6, 2016 -- AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), is hosting a live webcast on the phase 3 interim analysis results of masitinib in the treatment of amyotrophic lateral sclerosis (ALS) with key opinion leaders from this disease.

The webcast call will be held on Friday 8 April 2016 from 5.30pm to 6.30pm CET.

The web conference will provide the opportunity to understand:

• The design of the phase 3 study
• The outcome of the interim analysis and its implication for the study, in particular:
  • Why is the study not stopped
  • Why is the treatment effect at the interim analysis not disclosed
• The next steps anticipated with regulatory agencies
• The interpretation of the results on:
  • Primary analysis
  • Sensitivity analysis
  • Secondary endpoints
  • Safety
• The mechanism of action of masitinib in ALS
• The current IP position of masitinib in ALS
• Incidence and prevalence of ALS

It will be followed by a Q&A session with the management and KOL participating to the study.

The following experts in this disease will participate:

• Dr Jesus S. Mora, international coordinator of the study
  ALS Unit, Hospital Carlos III
  Madrid, Spain
   
• Dr Angela Genge

            Montreal Neurological Institute and Hospital
            Montreal, Canada

• Dr Conrado Estol
  STAT Research

            Buenos Aires, Argentina
             

• Dr Adriano Chiol
  AO città della salute e della scienza di Torino-ospedale le Molinette

            Torino, Italy

• Dr Luis Barbeito

            Institut Pasteur de Montevideo
Montevideo, Uruguay

• Pr Olivier Hermine

            Division of Hematology/Oncology, Necker University Hospital
            Paris, France

About masitinib
Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglia and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases.

About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a  class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous lines of treatment in cancers, inflammatory diseases, and central nervous system diseases, both in human and animal health.

AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine in Europe and in the USA. The company is currently pursuing twelve phase 3 studies in human medicine in first-line and second-line GIST, metastatic melanoma expressing JM mutation of c-Kit, multiple myeloma, metastatic colorectal cancer, metastatic prostate cancer, pancreatic cancer, mastocytosis, severe asthma uncontrolled by oral corticosteroid, Alzheimer's Disease, progressive forms of multiple sclerosis, and amyotrophic lateral sclerosis. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science's website: www.ab-science.com

This document contains prospective information. No guarantee can be given as for the realization of these forecasts, which are subject to those risks described in documents deposited by the Company to the Authority of the financial markets, including trends of the economic conjuncture, the financial markets and the markets on which AB Science is present.

*   *   *

AB Science - Financial Communication & Media Relations
[email protected]

CP Eng http://hugin.info/155655/R/2001374/738411.pdf

HUG#2001374